Sakar Healthcare Ltd (NSE:SAKAR) Q3 2026 Earnings Call Highlights: Impressive Revenue Growth …

GuruFocus News

Fri, February 13, 2026 at 10:07 AM GMT+9 3 min read

In this article:

SAKAR.NS

+1.07%

This article first appeared on GuruFocus.

**Revenue (Q3 FY26):** INR 7,034 lakhs, a 62% year-on-year growth from INR 4,342 lakhs in Q3 FY25.

**EBITDA (Q3 FY26):** INR 1,859 lakhs, up from INR 117 lakhs in Q3 FY25, with EBITDA margins at 26%.

**Profit After Tax (Q3 FY26):** INR 1,025 lakhs, a 126% year-on-year increase from INR 453 lakhs in Q3 FY25.

**Gross Margin (Q3 FY26):** 49%.

**Revenue (9 months FY26):** INR 18,064 lakhs, a 42% increase from INR 12,734 lakhs in 9 months FY25.

**EBITDA (9 months FY26):** INR 4,265 lakhs, a 26% increase from INR 3,396 lakhs in 9 months FY25.

**Profit After Tax (9 months FY26):** INR 1,946 lakhs, a 66% year-on-year growth from INR 1,174 lakhs in 9 months FY25.

Warning! GuruFocus has detected 8 Warning Signs with NSE:SAKAR.

Is NSE:SAKAR fairly valued? Test your thesis with our free DCF calculator.

Release Date: February 11, 2026

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Sakar Healthcare Ltd (NSE:SAKAR) reported a robust 62% year-on-year growth in revenue for Q3 FY26, reaching INR7,034 lakhs.

The company's oncology vertical demonstrated strong traction, with significant contributions to revenue growth and profitability.

The EU-GMP approved oncology facility at Bavla has gained strategic relevance, enabling Sakar Healthcare to serve stringent regulated markets.

Profit after tax for Q3 FY26 increased by 126% year-on-year, supported by operating leverage and a better product mix.

The company has successfully submitted 102 oncology dossiers globally, with 11 receiving marketing authorizations, enhancing its market presence.

Negative Points

The company faces challenges in regulatory approvals, which can impact the timely commercialization of products.

Employee costs have increased, with a sequential rise from 8.3% to 9.9% of revenue, potentially affecting margins.

The tax rate for the quarter was lower due to MAT credit utilization, which may not be sustainable in the long term.

The company is heavily reliant on the oncology segment for growth, which could pose risks if market conditions change.

There is uncertainty regarding the timelines for marketing authorizations in Western Europe, which could delay revenue realization.

Q & A Highlights

Q: Can you provide details on the oncology revenues for Q3 and the nine months, including the split between domestic and export markets? A: The Q3 turnover for the oncology business was 31 crores, with 19 crores from exports, primarily to the EU, and 12 crores from domestic sales. For the nine months, the turnover was 69.45 crores, with 30.81 crores from exports and 8.62 crores from domestic sales. - Bikramjit Ghosh, Analyst

Story Continues  

Q: What is the status of the technology transfer and approvals for oncology products in the EU? A: We have 10 molecules in the process of transfer, with approvals already received for imatinib and another product. We expect two more approvals in the coming months and aim to complete the tech transfer process for all molecules within the next two quarters. - Dharmesh Thaker, Chief Financial Officer

Q: Can you explain the increase in employee costs and whether this is expected to stabilize? A: The employee cost increased from 8 crores in Q2 to 9.5 crores in Q3, mainly due to research-related expenses. We expect these costs to stabilize moving forward. - Bikramjit Ghosh, Analyst

Q: What is the expected growth in oncology revenues for the next fiscal year? A: We anticipate a 60-70% year-on-year growth in oncology revenues for FY27, driven by increased approvals and market penetration. - Dharmesh Thaker, Chief Financial Officer

Q: Could you provide an update on the CapEx for FY26 and expectations for FY27? A: We have completed 39 crores in CapEx for FY26, primarily for plant and machinery. We do not foresee any major CapEx for FY27, as the current capacity setup is sufficient. - Bikramjit Ghosh, Analyst

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Terms and Privacy Policy

Privacy Dashboard

More Info